We identified a locus on chromosome 6q16.3-q24.2 (ref. 1) associated with childhood obesity that includes 2.4 Mb common to eight genome scans for type 2 diabetes (T2D) or obesity [1] [2] [3] [4] [5] [6] [7] [8] . Analysis of the gene ENPP1 (also called PC-1), a candidate for insulin resistance 9,10 , in 6,147 subjects showed association between a three-allele risk haplotype (K121Q, IVS20delT-11 and A-G+1044TGA; QdelTG) and childhood obesity (odds ratio (OR) = 1.69, P = 0.0006), morbid or moderate obesity in adults (OR = 1.50, P = 0.006 or OR = 1.37, P = 0.02, respectively) and T2D (OR = 1.56, P = 0.00002). The Genotype IBD Sharing Test suggested that this obesity-associated ENPP1 risk haplotype contributes to the observed chromosome 6q linkage with childhood obesity. The haplotype confers a higher risk of glucose intolerance and T2D to obese children and their parents and associates with increased serum levels of soluble ENPP1 protein in children. Expression of a long ENPP1 mRNA isoform, which includes the obesity-associated A-G+1044TGA SNP, was specific for pancreatic islet beta cells, adipocytes and liver. These findings suggest that several variants of ENPP1 have a primary role in mediating insulin resistance and in the development of both obesity and T2D, suggesting that an underlying molecular mechanism is common to both conditions.
We identified a locus on chromosome 6q16.3-q24.2 (ref. 1) associated with childhood obesity that includes 2.4 Mb common to eight genome scans for type 2 diabetes (T2D) or obesity [1] [2] [3] [4] [5] [6] [7] [8] . Analysis of the gene ENPP1 (also called PC-1), a candidate for insulin resistance 9, 10 , in 6,147 subjects showed association between a three-allele risk haplotype (K121Q, IVS20delT-11 and A-G+1044TGA; QdelTG) and childhood obesity (odds ratio (OR) = 1.69, P = 0.0006), morbid or moderate obesity in adults (OR = 1.50, P = 0.006 or OR = 1.37, P = 0.02, respectively) and T2D (OR = 1.56, P = 0.00002). The Genotype IBD Sharing Test suggested that this obesity-associated ENPP1 risk haplotype contributes to the observed chromosome 6q linkage with childhood obesity. The haplotype confers a higher risk of glucose intolerance and T2D to obese children and their parents and associates with increased serum levels of soluble ENPP1 protein in children. Expression of a long ENPP1 mRNA isoform, which includes the obesity-associated A-G+1044TGA SNP, was specific for pancreatic islet beta cells, adipocytes and liver. These findings suggest that several variants of ENPP1 have a primary role in mediating insulin resistance and in the development of both obesity and T2D, suggesting that an underlying molecular mechanism is common to both conditions.
We initially compared the phenotypic characteristics of 62 families with evidence for linkage of childhood obesity to 6q (defined by an individual pedigree Z score 41.0 in the two-lod-drop interval flanked by markers D6S434 and D6S1704) with the remaining 35 families from our previously published genome scan for childhood obesity 1 . The obese children in the 62 families showed a trend toward having greater area under the glycemia curve after glucose administration and a substantially lower insulinogenic index (Supplementary Table 1 online). We found that 3.1% of the obese children in the 62 families were glucose-intolerant or diabetic, compared with none of the children in the other 35 families, and 13.8% of the parents of these children had T2D, compared with 3.2% of the parents in the other families (P ¼ 0.018). Therefore, the obesity susceptibility gene(s) on chromosome 6q may be also involved in glucose homeostasis.
The two-lod-drop interval in the 62 families with evidence for linkage of childhood obesity to 6q (ref. 1) covers 41.4 Mb and includes 166 referenced genes. We narrowed this region to a 2.4-Mb interval between markers D6S1656 and D6S270 using overlapping published linkage results for chromosome 6q16.1-q27 with obesity 2 , insulin secretion 3,4 or T2D [5] [6] [7] [8] . In this interval, the best candidate was ectonucleotide pyrophosphatase phosphodiesterase, ENPP1 (also called plasma cell glycoprotein-1, PC-1). ENPP1 directly inhibits insulin-induced conformational changes of the insulin receptor, thereby affecting its activation and downstream signaling 9, 11 .
We analyzed the microsatellite marker D6S1656 in intron 1 of ENPP1, linked to childhood obesity in our initial genome scan, in a second replication set of 68 families with childhood obesity and observed modest evidence of linkage (MLS ¼ 0.83, P ¼ 0.04). Allele 10 of D6S1656 was also significantly undertransmitted to affected children in both the initial and replication sets (44 transmitted versus 69 untransmitted, uncorrected P ¼ 0.02).
We sequenced all coding regions of ENPP1 plus 1.3 kb upstream of the ATG start codon and downstream of the TGA stop codon in 48 obese children from families with evidence for linkage of childhood obesity to 6q and in 24 nonobese adults. We identified 8 SNPs in the upstream sequence, 6 in intron-exon junctions, 4 missense mutations, 3 synonymous mutations and 20 SNPs in the downstream sequence (Supplementary Table 2 online). Of these 41 polymorphisms, 24 were present in the public databases and 22 had minor allele frequencies 45%. We used pairwise linkage disequilibrium (LD) among the 24 most common SNPs to select a set of ten haplotype-tagging SNPs to be typed in all the samples.
We also sequenced 25 intronic or intergenic fragments showing a high degree of homology (470%) across puffer fish, rat and human genomes and identified an additional 11 SNPs with minor allele frequencies 45%. We added SNP T-G+5954TGA, which showed a trend for association with childhood obesity (P o 0.1) in a test set of 421 obese children and 298 control individuals to the set of SNPs to be analyzed in the whole sample set.
We genotyped 11 SNPs in 2,430 individuals, including 529 unrelated obese children, 696 unrelated morbidly obese adults and 1,205 lean normoglycemic adults. We used the lean adults as controls for both sets of cases because they had a long-term resistance against obesity. We observed associations between severe forms of obesity and six SNPs: IVS2delG +8, K121Q, IVS8T-G+27, IVS20delT-11, A-G+1044TGA and T-G+5954TGA (0.00008 o P o 0.03; 1.21 o OR o 1.37; Table 1 and Supplementary Table 3 online). The global P value, assessed by 10 5 permutations of obesity status among individuals, was 0.001. Analysis of the pooled data identified the strongest association for severe forms of obesity with the K121Q SNP (OR ¼ 1.37, 95% confidence interval (c.i.) ¼ 1.17-1.61, P ¼ 0.00008). The OR under a recessive model increased to 3.29 (95% c.i. ¼ 1.83-5.93, P ¼ 0.00003) with a significant departure from the additive model (P ¼ 0.02).
We then genotyped the K121Q SNP in an additional 184 multiplex families, including the 97 families from the childhood obesity genome scan and 87 nuclear families with adult severe obesity, in whom serum leptin levels were linked to chromosome 6q24 (ref. 12). Using the transmission disequilibrium test (TDT), we found that the Gln121 variant was significantly overtransmitted to obese offspring (76 transmitted versus 48 nontransmitted, P ¼ 0.01), supporting the results of the case-control analysis.
To confirm ENPP1 specificity for these associations, we genotyped 53 SNPs in the chromosome 6q region, spanning 580 kb and including the genes ARG1, CRSP3, ENPP3, ENPP1 and CTGF, in the initial set of 421 obese children and 298 control individuals (average density of one SNP per 10.9 kb). We identified three distinct regions of LD: one containing ARG1, CRSP3 and ENPP3, one containing ENPP1 alone and the third containing CTGF and 176 kb of noncoding sequence ( Fig. 1) . Eight SNPs were associated with both childhood obesity and childhood obesity with evidence for linkage to 6q (P o 0.05). Seven of these (K121Q, Celera dbSNP hcV1207989, C-T+164TGA, Celera dbSNP hcV1207974, A-G+1044TGA, G-T+1101TGA and C-T+ 1157TGA) mapped within ENPP1 (Fig. 2) , suggesting that the observed association with childhood obesity is due to SNPs in ENPP1.
We used a two-SNP analysis between the K121Q polymorphism and the six other obesity-associated SNPs to assess whether the SNPs had independent effects on the risk of obesity. A likelihood ratio test showed that only the SNPs IVS20delT-11 and G+1044TGA significantly modulated the effect of K121Q (P ¼ 0.03 and 0.04, respectively). For these two SNPs, the model with the best fit was a recessive one. This may account for the small observed deviation from HardyWeinberg equilibrium for these SNPs, as genotyping errors were ruled out by resequencing (data not shown).
To estimate the potential effects of combinations of the three SNPs on the risk of obesity, we carried out haplotype analysis using genotype data for K121Q, IVS20delT-11 and A-G+1044TGA from the whole set of 2,430 French subjects. Eight haplotypes were predicted, five with minor allele frequencies 45%. The three-allele wild-type haplotype (KTA) was less frequent in obese subjects than in controls (60.3% versus 64.0%, P ¼ 0.002; Table 2 ). In contrast, the three-allele risk haplotype (QdelTG) was strongly associated with severe forms of obesity (11.2% versus 7.5%, OR ¼ 1.58, P ¼ 0.00001, empirical P o 0.0001 for 10 5 simulations). Notably, the risk haplotype effect was of similar magnitude in morbidly obese adults and in childhood obesity (10.8% versus 7.9%, OR ¼ 1.50, P ¼ 0.006 and 11.7% versus 7.1%, OR ¼ 1.69, P ¼ 0.0006, respectively). The association was also supported by TDT analysis in the 184 families (w 2 ¼ 5.68, P ¼ 0.01; Table 2 ), whereas transmission distortion was excluded in a set of 458 French trios with unaffected children (w 2 ¼ 0.53, P ¼ 0.46) 13 . The risk haplotype was associated with obesity (10.3% versus 7.9%, OR ¼ 1.37, P ¼ 0.02) in an additional set of 717 adults with a less severe form of obesity (body mass index (BMI) between 30 and 40 kg m À2 ). 
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Several lines of evidence suggested that the ENPP1 risk haplotype affected the linkage with childhood obesity observed in the genome scan. First, we detected a higher frequency of the risk haplotype in individuals from families with evidence for linkage of childhood obesity to 6q (16.2% versus 7.1%, OR ¼ 2.37, P ¼ 0.004) than in those from other families (12.2% versus 7.1%, OR ¼ 1.65, P ¼ 0.16). After we removed 15 affected sibling pairs that shared the risk haplotype (from a total of 135 sibling pairs), the multipoint MLS lod score dropped from 4.06 to 1.6 at marker D6S287, and we obtained a new maximal score of 2.63 at a point 16 Mb centromeric to the original linkage peak, at marker D6S301. The Genotype IBD Sharing Test 14 also suggested a trend for a possible effect of the haplotype under an additive model (P ¼ 0.07), which became significant for a recessive model (P ¼ 0.03).
At least three ENPP1 SNPs are involved in the association with obesity. The Gln121 variant is believed to inhibit insulin signaling 15 more effectively than the wild type, but the functional effects of the risk haplotype are unknown. The ENPP1 protein has a proteolytic cleavage site, is cleaved at the surface of cells and is present in the circulation 16 . Thus, the protein serum level is a good estimate of its tissue expression 16 . Serum ENPP1 protein levels measured in 279 children whose weight varied widely showed a positive correlation with the Z score of BMI (Pearson correlation coefficient ¼ 0.1, P ¼ 0.05; Supplementary Fig. 1 online) . We then selected 89 lean children (mean BMI of 18.4 ± 2.5 kg m À2 , mean age of 13.3 ± 2.6 y; n ¼ 50 girls and 39 boys), to fix the confounder BMI, and analyzed the effect of the three SNPs on ENPP1 levels. The presence of at least one copy of Gln121, IVS20delT-11 and G+1044TGA variants was associated with a highly significant increase of ENPP1 levels (28.6 ng ml À1 versus 24.1 ng ml À1 , P ¼ 0.008; Fig. 3) , suggesting that the obesity-associated haplotype not only impairs insulin binding but also enhances ENPP1 levels of expression.
We then assessed the contribution of the risk haplotype to the variation of obesity-related phenotypes in 474 obese children. Obese children with the obesity-associated risk haplotype had an increase in fasting glycemia of 0.17 mmol l À1 (P ¼ 0.002) with a higher prevalence of glucose intolerance and T2D (OR ¼ 3.43, P ¼ 0.02). Parents carrying the risk haplotype had a 2.35 times greater risk of developing T2D (P ¼ 0.005). This risk was higher in the subset of obese parents (OR ¼ 3.26, P ¼ 0.0005), with no increase in the risk of T2D observed in nonobese parents carrying the risk haplotype (OR ¼ 0.86, P ¼ 0.9). We compared an additional nonoverlapping cohort of 752 unrelated French individuals with T2D and familial history of the disease with the previously described 556 middle-aged nonobese normoglycemic subjects (mean age of 55 ± 6 y). The individuals with T2D had a significant excess of the risk haplotype (10.7% versus 7.1%, OR ¼ 1.44, P ¼ 0.005), further supporting the idea that ENPP1 SNPs affect glucose homeostasis in French individuals. We replicated this finding in 1,261 unrelated Austrian individuals, 503 who had T2D and 758 nonobese normoglycemic individuals (9.8% versus 6.3%, OR ¼ 1.68, P ¼ 0.001). Using the Mantel-Haenszel adjusted OR, under a fixed effects model, in the pooled cohorts of 2,569 European subjects strengthened the association of the risk haplotype with T2D (10.4% versus 6.6%, combined OR ¼ 1.56, P ¼ 0.00002). In summary, these findings indicate that both obesity and T2D, especially in obese subjects, are associated with ENPP1 genetic variability and, specifically, one three-allele risk haplotype. This provides genetic evidence for the recently described link between obesity in childhood and the high risk for T2D in adolescence and early adulthood 17 , providing the first common molecular mechanism for this deleterious association.
We carried out RT-PCR on cDNAs from a wide range of human tissues including brain, muscle, liver, adipocyte (subcutaneous and omental) and purified pancreatic islet beta cells. Taking into account that five ENPP1 isoforms are known (National Center for Biotechnology Information's AceView), we designed primers to amplify the region between exons 7 and 12, common to at least three transcripts, and found ubiquitous expression ( Supplementary Fig. 2 online) . We then designed primers to specifically amplify the long mRNA isoform (larger 3¢ untranslated region (UTR) with 1,170 bases downstream of the TGA stop codon) that includes the obesity-associated SNP A-G+1044TGA. The long form was expressed only in pancreatic beta cells, adipocytes and liver, three key tissues for glucose homeostasis ( Supplementary Fig. 2 online) .
We assessed the contribution of the obesity-associated ENPP1 risk haplotype to the observed linkage with childhood obesity using several methods but found only a moderate excess of transmission of this haplotype to affected offspring. This finding suggests that the risk haplotype is contributory but not sufficient to explain the linkage with childhood obesity. Additional SNPs in the noncoding regions of the ENPP1 locus may account for part of the observed linkage, such as SNP T-G+5954TGA, located in a highly conserved region. This variation predicts loss of binding to the insulin promoter factor IPF1. Alternatively, more than one gene may explain the linkage with obesity and T2D on 6q. Recent data (C. Jenkinson, unpublished data) supports the idea that ENPP1 SNPs contribute to linkage for insulin fasting levels in Mexican Americans 3 .
Only the ENPP1 K121Q missense mutation has been suggested to be associated with insulin resistance or T2D in limited studies 18 . The 3¢ UTR SNP (A-G+1044TGA) belongs to an isoform specifically expressed in three highly insulin-responsive human tissues (pancreatic islet beta cell, adipocyte and liver). Mice given an adenovirus expression construct overexpressing this gene in hepatocytes show insulin resistance and glucose intolerance 10 . Although the exonic K121Q amino acid substitution directly inhibits insulin receptor by a nonenzymatic mechanism 15 , the other non-coding SNPs may have their effect by modifying gene expression, protein production or splicing. This hypothesis is supported by the findings of increased serum protein levels in children carrying the ENPP1 obesity risk haplotype and by the rise of ENPP1 levels with adiposity.
Higher protein expression may mimic the effects of insulin receptor inactivation in the brain, where insulin has potent anorectic actions, or in the skeletal muscle, both leading to increased fat mass 19, 20 . Obese children carrying the ENPP1 risk haplotype often have glucose intolerance and a family history of T2D. This suggests that the exaggerated insulin resistance conferred by inherited increased ENPP1 expression in the context of a 'westernized' obesogenic environment may contribute to excessive fat accumulation. The ENPP1 Gln121 variant was recently associated with increased BMI in the UK general population 21 . Data presented here support the idea that primary insulin resistance has a causative effect on childhood obesity. According to this hypothesis, insulin resistance-induced fasting hyperinsulinemia was a strong predictor for the subsequent development of obesity in children of various ethnic groups 22 .
In conclusion, this study strongly supports a genetic link between ENPP1 gene variants and chromosome 6q-linked childhood polygenic obesity and adult obesity and T2D. This provides an insight into the molecular basis for the physiologic association between insulin resistance and obesity and presents a new perspective for prevention and treatment of these conditions.
METHODS
Subjects. Phenotypic characteristics are summarized in Supplementary Table 4 online. We studied 529 unrelated obese children. We collected 336 pedigrees with at least one obese child and recruited 106 additional obese children in Toulouse and 87 in Paris. Children with a BMI greater than the 97 th percentile of BMI for age and sex were diagnosed as obese. We used a set of 696 unrelated morbidly obese (BMI Z 40 kg m À2 ) and 717 unrelated moderately obese (BMI of 30-40 kg m À2 ) adults. We also used 87 pedigrees with adult obesity for TDT. The 752 individuals with T2D were recruited at the Sud Francilien Hospital or at the CNRS Lille. The first set of 556 control subjects was selected from the SUVIMAX population 23 . The second set of 649 control individuals was recruited at the CNRS Lille and through the ''Fleurbaix-Laventie Ville Santé'' study. The 1,261 Austrian subjects were previously described 24 . To justify the use of non-age-matched controls, we genotyped the K121Q, IVS20delT-11 and A-G+1044TGA polymorphisms in 198 control children 25 and found very concordant frequencies for the risk haplotype (7.8%) in comparison with control adults. The 458 control trios (two parents and one lean child) were selected from the ''Fleurbaix-Laventie Ville Santé'' cohort 25 . The genetic study was approved by Ethical Committees of Hotel Dieu in Paris and CHRU in Lille. We obtained the Z score of BMI according to Cole's method. We calculated insulinogenic index as previously described 26 .
Linkage analysis. In 68 nuclear families, comprising 306 individuals, we genotyped five polymorphic markers (D6S1720, D6S434, D6S287, D6S1656 and D6S292) covering the linkage interval of the initial genome-wide study 1 . We carried out two-point and multipoint analyses using the MLS test implemented in the GeneHunter software.
Mutation screening. We screened the 25 exons and UTRs (upstream 5¢ UTR and downstream 3¢ UTR) using DHPLC (Transgenomic) in 48 unrelated obese children randomly selected from families contributing to the linkage at chromosome 6q16-q24 and in 24 unrelated nonobese normoglycemic control subjects selected from French pedigrees. We sequenced variant profiles using an automated ABI Prism 3700 DNA sequencer in combination with the Big Dye Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems).
Genotyping. We genotyped microsatellites using a fluorescence-based semiautomated technique on automated DNA sequencing machines (ABI 377, PE ABI). Primers were synthesized by MWG Biotech. We genotyped SNPs with LightCycler LightTyper (Roche Diagnostics), with TaqMan (Applied Biosystems) or by direct sequencing. Probes for LightCycler and LightTyper were synthesized by TIB Molbiol Syntheselabor. For coverage of the 580-kb region, we selected SNPs with an allele frequency 410% in individuals of European descent using the Applied Biosystem SNP Viewer II software. To avoid SNP genotyping errors, we systematically regenotyped 10% of DNA samples for further verification. We found concordance rates of 100% for all SNPs.
Statistical analyses. We compared allele frequencies between cases and controls using the w 2 test and computed the P value empirically with the program CLUMP. We determined haplotype frequencies and compared them between groups using UNPHASED software. We evaluated the effect of haplotypes on qualitative or quantitative trait variation using the subprograms cocaphase and qt-phase of UNPHASED. We tested independence of association with the software THESIAS 27 . THESIAS also implements an EM algorithm and allows for likelihood testing of models of haplotype effect in a linear framework. We used this program to test whether the effect of each SNP, on obesity status, was independent from the effect of K121Q alone. TDT analyses on SNPs and 
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haplotypes were done by the TDT method implemented in UNPHASED. Because of low LD between the three SNPs of the risk haplotype, we used only the unambiguous haplotypes to obtain a true TDT robust to population stratification. To evaluate the effect of the risk haplotype on linkage, we used the Genotype IBD Sharing Test procedure 14 .
LD analysis. We investigated LD among 24 identified ENPP1 SNPs and among 53 SNPs in the 580-kb ENPP1 region. We estimated pairwise delta values (correlation coefficients between SNPs) from genotypes and visualized the results using the GOLD program.
ENPP1 mRNA expression. We used human cDNAs from MTC Panel (BD Biosciences Clontech), subcutaneous and omental adipocytes (provided by G. Fruhbeck, University of Navarra, Pamplona, Spain) and FACS-purified pancreatic beta cells (provided by the Human Pancreatic Cell Core Facility, University Hospital, Lille, France) for mRNA expression analysis. We confirmed beta-cell purity by immunochemistry (98% insulin-positive cells) and PCR (absence of amplification with chymotrypsin primers, specific for exocrine cells). We carried out PCR in a 25-ml mixture containing 10 mM Tris-HCl, 1.5 mM MgCl 2 , 50 mM KCl, 10 mM each dNTP, 2.5 U Taq polymerase (Promega), 30 mM both forward primer and reverse primers and 3 ml of single-stranded cDNA. We heated the mixtures at 95 1C for 2 min and subjected them to 45-cycle amplification at 95 1C for 30 s, 68 1C for 2 min and 72 1C for 2 min, followed by 10 min at 72 1C. We separated PCR products on 2% (w/v) agarose gels and visualized them using ethidium bromide and ultraviolet transillumination.
ENPP1 protein serum assays. We measured ENPP1 serum level using the ELISA previously described 16 .
URLs. National Center for Biotechnology Information's AceView is available at http://www.ncbi.nih.gov/IEB/Research/Acembly/av.cgi?db¼human&l¼ENPP1. UNPHASED software is available at http://www.mrc-bsu.cam.ac.uk/personal/ frank/. The GOLD program is available at http://www.sph.umich.edu/csg/ abecasis/GOLD/.
Note: Supplementary information is available on the Nature Genetics website.
